Published in Virology on January 05, 2013
Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev (2013) 1.06
Epstein-barr virus vaccines. Clin Transl Immunology (2015) 0.88
Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus. Virology (2015) 0.77
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. J Virol (2015) 0.75
Characterization and phylogenetic analysis of Varicella-zoster virus strains isolated from Korean patients. J Microbiol (2017) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) (1982) 5.29
Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2007) 4.60
Loss of vaccine-induced immunity to varicella over time. N Engl J Med (2007) 4.55
Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis (1974) 4.41
Herpes simplex virus encephalitis in human UNC-93B deficiency. Science (2006) 4.26
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
The incidence of herpes zoster. Arch Intern Med (1995) 3.87
The effectiveness of the varicella vaccine in clinical practice. N Engl J Med (2001) 3.66
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Live vaccine used to prevent the spread of varicella in children in hospital. Lancet (1974) 3.24
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol (1995) 2.87
Maternal and neonatal herpes simplex virus infections. N Engl J Med (2009) 2.85
Zoster sine herpete, a clinical variant. Ann Neurol (1994) 2.84
Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med (2002) 2.73
The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med (1991) 2.62
Immune responses to varicella-zoster in the aged. Arch Intern Med (1982) 2.59
Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)? Clin Infect Dis (2011) 2.56
Effectiveness over time of varicella vaccine. JAMA (2004) 2.52
Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol (2004) 2.51
Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol (1992) 2.37
Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37
Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet (2002) 2.34
Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis (2007) 2.33
Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol (2011) 2.29
The postmarketing safety profile of varicella vaccine. Vaccine (2000) 2.18
Neurological disease produced by varicella zoster virus reactivation without rash. Curr Top Microbiol Immunol (2010) 2.17
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine (2002) 2.12
Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep (1996) 2.09
Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med (1983) 2.04
Varicella prevention in the United States: a review of successes and challenges. Pediatrics (2008) 1.99
Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis (2003) 1.91
Demonstration of varicella-zoster virus infection in the muscularis propria and myenteric plexi of the colon in an HIV-positive patient with herpes zoster and small bowel pseudo-obstruction (Ogilvie's syndrome). Am J Gastroenterol (2001) 1.87
Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med (2004) 1.85
Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology (2011) 1.85
Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection. N Engl J Med (1966) 1.72
Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol (2008) 1.71
Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA (1984) 1.65
Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J Virol (1989) 1.62
Zoster immune globulin. A further assessment. N Engl J Med (1974) 1.57
Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis (2000) 1.55
The safety profile of varicella vaccine: a 10-year review. J Infect Dis (2008) 1.50
A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. J Gen Virol (2010) 1.49
Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48
Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics (2011) 1.46
Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis (2011) 1.45
Ogilvie syndrome and herpes zoster: case report and review of the literature. J Emerg Med (2009) 1.45
Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell (2004) 1.45
Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut (1993) 1.42
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Airborne transmission of chickenpox in a hospital. N Engl J Med (1980) 1.39
Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis (2010) 1.36
Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics (1994) 1.36
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis (2012) 1.36
Clinical reinfection with varicella-zoster virus. J Infect Dis (1984) 1.34
HSV-2: in pursuit of a vaccine. J Clin Invest (2011) 1.29
Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis (1988) 1.28
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
Varicella zoster virus (VZV) infects and establishes latency in enteric neurons. J Neurovirol (2011) 1.28
Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis (1992) 1.26
Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? Clin Infect Dis (1997) 1.24
A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis (2012) 1.20
Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children. Trans Am Clin Climatol Assoc (2012) 1.18
Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis (2008) 1.18
Are stressful life events risk factors for herpes zoster? J Am Geriatr Soc (1990) 1.16
Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis (2010) 1.14
Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol (2010) 1.14
Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics (1983) 1.13
Restricted varicella-zoster virus transcription in human trigeminal ganglia obtained soon after death. J Virol (2012) 1.12
Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol (2010) 1.11
Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics (2001) 1.10
Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol (2010) 1.10
Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatr Infect Dis J (1991) 1.06
Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol (2009) 1.05
Neonatal herpes: what have we learned. Semin Pediatr Infect Dis (2005) 1.05
Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J (2010) 1.04
An outbreak of airborne nosocomial varicella. Pediatrics (1982) 1.03
Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics (2007) 1.02
Fatal varicella-zoster virus meningoradiculitis without skin involvement. Ann Neurol (1991) 1.02
Varicella-zoster virus human ganglionic latency: a current summary. J Neurovirol (2010) 1.01
Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002-2008. Pediatr Infect Dis J (2009) 1.01
Fatal varicella-zoster virus antigen-positive giant cell arteritis of the central nervous system. Pediatr Infect Dis J (2000) 1.00
A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis (1977) 1.00
The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect (2004) 1.00
Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis (2008) 0.97
Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol (2012) 0.97
Visceral zoster as the presenting feature of disseminated herpes zoster. J Am Acad Dermatol (2002) 0.89
Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster. J Clin Microbiol (2012) 0.89
Clinical and biological differences between recurrent herpes simplex virus and varicella-zoster virus infections. JAMA (1990) 0.88
Subclinical reactivation of varicella zoster virus in all stages of HIV infection. J Neurol Sci (2011) 0.88
Transmission of chickenpox in a school setting prior to the observed exanthem. Am J Dis Child (1989) 0.88
Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979-2007. Clin Infect Dis (2012) 0.87
Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis (2008) 0.86
Simian varicella virus infection of Chinese rhesus macaques produces ganglionic infection in the absence of rash. J Neurovirol (2012) 0.85
Association of an attack of varicella and an achalasia. Am J Gastroenterol (1995) 0.85